{
  "company": {
    "name": "Amolyt Pharma",
    "website": "https://amolytpharma.com/",
    "record": "https://startuphistory.org/c/amolytpharma.com"
  },
  "status": null,
  "history_since": "2020-07-06T11:21:07.000Z",
  "baseline": {
    "snapshot_id": "1e5e45b13db39dd8ac6a55ea82eed4401da2a1e1190112f776c60be22d7c4318",
    "observed_at": "2020-07-06T11:21:07.000Z",
    "headline": "Advancing peptides for the treatment of rare endocrine and metabolic disorders",
    "description": "We are building on our team's established expertise in therapeutic peptides to deliver life-changing treatments to patients suffering from rare endocrine and metabolic diseases.",
    "evidence": "https://web.archive.org/web/20200706112107/https://amolytpharma.com/",
    "evidence_kind": "internet_archive",
    "facts": {
      "version": 1,
      "pages": [
        {
          "page": "home",
          "customers": [],
          "investors": [
            "LSP",
            "Novo Holdings",
            "Kurma Partners",
            "OrbiMed",
            "Pontifax",
            "Partners Healthcare",
            "bpifrance",
            "Turenne",
            "sham partageons plus",
            "CA",
            "SofiMAC",
            "initiative OCTALFA",
            "Kreaxi"
          ],
          "prices": [],
          "compliance": [],
          "funding": [
            "inception, Alizé Pharma 3, now Amolyt Pharma, has raised 3.3 M€ ($3.6 M) in seed funding, followed by a 67 M€ ($74 M) Series A financing from a strong international syndicate of investors."
          ]
        }
      ]
    },
    "basis": "first_observation",
    "is_change": false
  },
  "live_captures": 0,
  "last_checked": null,
  "live_status": "offline",
  "messaging": [
    {
      "quote_observed_at": "2024-08-10T22:39:21.000Z",
      "variants": [
        {
          "headline": "Advancing peptides for the treatment of rare endocrine and metabolic disorders",
          "subhead": "We are building on our team's established expertise in therapeutic peptides to deliver life-changing treatments to patients suffering from rare endocrine and metabolic diseases.",
          "observed_at": "2020-07-06T11:21:07.000Z",
          "evidence": "https://web.archive.org/web/20200706112107/https://amolytpharma.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Advancing peptides for the treatment of rare endocrine and metabolic disorders",
          "subhead": "We are building on our team's established expertise in therapeutic peptides to deliver life-changing treatments to patients suffering from rare endocrine and metabolic diseases.",
          "observed_at": "2021-01-18T03:25:55.000Z",
          "evidence": "https://web.archive.org/web/20210118032555/https://amolytpharma.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Advancing peptides for the treatment of rare endocrine and metabolic disorders",
          "subhead": "We are building on our team's established expertise in therapeutic peptides to deliver life-changing treatments to patients suffering from rare endocrine and metabolic diseases.",
          "observed_at": "2021-08-03T00:10:37.000Z",
          "evidence": "https://web.archive.org/web/20210803001037/https://amolytpharma.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Advancing peptides for the treatment of rare endocrine and related diseases",
          "subhead": "We are building on our team's established expertise in therapeutic peptides to deliver life-changing treatments to patients suffering from rare endocrine and metabolic diseases.",
          "observed_at": "2022-01-31T10:28:52.000Z",
          "evidence": "https://web.archive.org/web/20220131102852/https://amolytpharma.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Advancing peptides for the treatment of rare endocrine and related diseases",
          "subhead": "We are building on our team's established expertise in therapeutic peptides to deliver life-changing treatments to patients suffering from rare endocrine and metabolic diseases.",
          "observed_at": "2022-07-02T10:52:35.000Z",
          "evidence": "https://web.archive.org/web/20220702105235/https://amolytpharma.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Advancing peptides for the treatment of rare endocrine and related diseases",
          "subhead": "We are building on our team's established expertise in therapeutic peptides to deliver life-changing treatments to patients suffering from rare endocrine and metabolic diseases.",
          "observed_at": "2023-01-06T19:21:09.000Z",
          "evidence": "https://web.archive.org/web/20230106192109/https://amolytpharma.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Advancing peptides for the treatment of rare endocrine and related diseases",
          "subhead": "We are building on our team's established expertise in therapeutic peptides to deliver life-changing treatments to patients suffering from rare endocrine and metabolic diseases.",
          "observed_at": "2023-07-03T19:47:29.000Z",
          "evidence": "https://web.archive.org/web/20230703194729/https://amolytpharma.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Advancing peptides for the treatment of rare endocrine and related diseases",
          "subhead": "We are building on our team's established expertise in therapeutic peptides to deliver life-changing treatments to patients suffering from rare endocrine and metabolic diseases.",
          "observed_at": "2024-01-04T07:26:07.000Z",
          "evidence": "https://web.archive.org/web/20240104072607/https://amolytpharma.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Advancing peptides for the treatment of rare endocrine and related diseases",
          "subhead": "We are building on our team's established expertise in therapeutic peptides to deliver life-changing treatments to patients suffering from rare endocrine and metabolic diseases.",
          "observed_at": "2024-07-03T00:35:49.000Z",
          "evidence": "https://web.archive.org/web/20240703003549/https://amolytpharma.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Advancing peptides for the treatment of rare endocrine and related diseases",
          "subhead": "We are building on our team's established expertise in therapeutic peptides to deliver life-changing treatments to patients suffering from rare endocrine and metabolic diseases.",
          "observed_at": "2024-08-10T22:39:21.000Z",
          "evidence": "https://web.archive.org/web/20240810223921/https://amolytpharma.com/",
          "evidence_kind": "internet_archive"
        }
      ],
      "headline": "Advancing peptides for the treatment of rare endocrine and related diseases",
      "subhead": "We are building on our team's established expertise in therapeutic peptides to deliver life-changing treatments to patients suffering from rare endocrine and metabolic diseases.",
      "from": "2020-07-06T11:21:07.000Z",
      "to": "2024-08-10T22:39:21.000Z",
      "captures": 10,
      "evidence": "https://web.archive.org/web/20240810223921/https://amolytpharma.com/",
      "evidence_kind": "internet_archive",
      "seen": {
        "between": {
          "from": "2020-07-06T11:21:07.000Z",
          "to": "2024-08-10T22:39:21.000Z"
        }
      },
      "current": true
    }
  ],
  "changes": [
    {
      "n": 1,
      "id": "page-1e5e45b13db39dd8ac6a55ea82eed4401da2a1e1190112f776c60be22d7c4318:2d31256c6667c45f4b37cf9967c44d336b1b1c2a33982349a0e1279607068ec9:hiring:20dd4c09cc4ab0aa",
      "before_evidence": "https://web.archive.org/web/20200706112107/https://amolytpharma.com/",
      "before_evidence_kind": "internet_archive",
      "kind": "hiring",
      "label": "Hiring",
      "summary": "Added a careers page.",
      "between": {
        "from": "2020-07-06T11:21:07.000Z",
        "to": "2021-01-18T03:25:55.000Z"
      },
      "evidence": "https://web.archive.org/web/20210118032555/https://amolytpharma.com/",
      "evidence_kind": "internet_archive",
      "basis": "page_facts",
      "topic": "https://startuphistory.org/t/added-careers-page"
    }
  ],
  "update": null,
  "method": {
    "version": "messaging-v1",
    "description": "https://startuphistory.org/method"
  },
  "license": "CC-BY-4.0",
  "cite": "StartupHistory, “Amolyt Pharma” company record, https://startuphistory.org/c/amolytpharma.com"
}